Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Desoximetasone

FDA-approved product (cream, topical), marketed as Desoximetasone, Topicort, Topicort Lp.

Registered studies
10
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Desoximetasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Desoximetasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Desoximetasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluating Treatment Resistant Dermatitis TaroIIR

    NCT03050294 · start 2017-02-01

    Registered record
    Registry ID
    NCT03050294
    Conditions
    Atopic Dermatitis; Psoriasis
    Interventions
    Phone calls; Desoximetasone 0.25% spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-02-01
    Completion
    2017-06-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Psoriasis
    InterventionPhone calls; Desoximetasone 0.25% spray
    PhasePhase 4
    Registry statusCompleted

  • Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

    NCT02985736 · start 2016-09

    Registered record
    Registry ID
    NCT02985736
    Conditions
    Psoriasis
    Interventions
    Topicort Topical Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-09
    Completion
    2017-01-27
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionTopicort Topical Spray
    PhasePhase 4
    Registry statusCompleted

  • Topical Psoriasis Study for Patients Receiving Biologic Therapy

    NCT02983981 · start 2016-03

    Registered record
    Registry ID
    NCT02983981
    Conditions
    Psoriasis
    Interventions
    Topicort Topical Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionTopicort Topical Spray
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

    NCT02749656 · start 2016-01-01

    Registered record
    Registry ID
    NCT02749656
    Conditions
    Scalp Psoriasis
    Interventions
    0.25% Desoximetasone cream (Topoxy®); 0.25% Desoximetasone cream (Topicorte®); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-01-01
    Completion
    2018-12
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScalp Psoriasis
    Intervention0.25% Desoximetasone cream (Topoxy®); 0.25% Desoximetasone cream (Topicorte®); Placebo
    PhasePhase 3
    Registry statusUnknown

  • Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

    NCT02595073 · start 2015-09-04

    Registered record
    Registry ID
    NCT02595073
    Conditions
    Atopic Dermatitis
    Interventions
    DSXS; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09-04
    Completion
    2017-08-29
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionDSXS; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

    NCT02340169 · start 2015-01-23

    Registered record
    Registry ID
    NCT02340169
    Conditions
    Plaque Psoriasis
    Interventions
    Topicort® (desoximetasone) Topical Spray, 0.25%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01-23
    Completion
    2021-11-22
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionTopicort® (desoximetasone) Topical Spray, 0.25%
    PhasePhase 4
    Registry statusCompleted

  • Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

    NCT01206387 · start 2010-08

    Registered record
    Registry ID
    NCT01206387
    Conditions
    Psoriasis
    Interventions
    Desoximetasone Spray 0.25%; placebo comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDesoximetasone Spray 0.25%; placebo comparator
    PhasePhase 3
    Registry statusCompleted

  • Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

    NCT01206660 · start 2010-08

    Registered record
    Registry ID
    NCT01206660
    Conditions
    Psoriasis
    Interventions
    Desoximetasone Spray 0.25%; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDesoximetasone Spray 0.25%; placebo
    PhasePhase 3
    Registry statusCompleted

  • Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

    NCT01043393 · start 2010-02

    Registered record
    Registry ID
    NCT01043393
    Conditions
    Psoriasis
    Interventions
    Desoximetasone 0.25% spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDesoximetasone 0.25% spray
    PhasePhase 2
    Registry statusCompleted

  • Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

    NCT01018134 · start 2009-11

    Registered record
    Registry ID
    NCT01018134
    Conditions
    Psoriasis
    Interventions
    Desoximetasone 0.05% once daily; Desoximetasone 0.05% twice daily; Desoximetasone 0.25% once daily; Desoximetasone 0.25% once daily; Vehicle once daily; Vehicle twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-05
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDesoximetasone 0.05% once daily; Desoximetasone 0.05% twice daily; Desoximetasone 0.25% once daily; Desoximetasone 0.25% once daily +2 more
    PhasePhase 2
    Registry statusCompleted